NCT07166146 Timing and Outcomes of Recovery After intraCerebral Hemorrhage
| NCT ID | NCT07166146 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Intracerebral Haemorrhage |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-06-04 |
| Primary Completion | 2027-03-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-06-04 with a primary completion date of 2027-03-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The TORCH registry is a prospective, observational cohort study, which will collect detailed, longitudinal data on the clinical characteristics, treatment modalities, and outcomes of patients with ICH. By leveraging a wide array of surgical interventions - including endoscopic surgery, minimally invasive surgery combined with urokinase, and craniotomy - the TORCH registry intends to provide a granular view of early hematoma evacuation surgical interventions and their impact on patient recovery and quality of life.
Eligibility Criteria
Inclusion Criteria: * Subject Age is ≥18 to ≤80 years * Subject with a Head CT/CTA that demonstrates an acute, spontaneous, primary, supratentorial ICH, assessed via standard of care techniques * Subject recieving a surgery intervention * Subject has a NIHSS score ≥ 6 or GCS score 5≤GCS≤15 * Subject has a baseline Modified Rankin Scale (mRS) Score ≤ 1 Exclusion Criteria: * Secondary intracerebral hemorrhage (with leading cause, e.g., Moyamoya disease, arteriovenous malformation, intracranial aneurysm, tumor, brain trauma) * Pre-stroke life expectancy \< 1 year for severe comorbidities (e.g., Progressive malignant tumor, severe chronic heart failure \[NYHA: III-IV\], severe chronic obstructive pulmonary disease \[III-IV\], chronic kidney disease requiring hemodialysis) * Patients with platelet count \< 100,000, INR \> 1.4, or an elevated PT or APTT (reversal of coumadin is permitted but the patient must not require coumadin during the acute hospitalization). Irreversible coagulopathy either due to medical condition or prior to randomization * Pregnant (positive pregnancy test) or lactating females (likelihood of altered coagulation function associated with the high estrogen/progesterone state) * Irreversibly impaired brainstem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS less than or equal to 4
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07166146 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Intracerebral Haemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07166146 currently recruiting?
Yes, NCT07166146 is actively recruiting participants. Contact the research team at hongtao.edu@gmail.com for enrollment information.
Where is the NCT07166146 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07166146 clinical trial?
NCT07166146 is sponsored by Xuanwu Hospital, Beijing. The trial plans to enroll 500 participants.